Pimavanserin metabolite M26 | 1134815-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Pimavanserin metabolite M26
• 英文别名: 1-[(4-fluorophenyl)methyl]-3-[[4-(2-hydroxy-2-methylpropoxy)phenyl]methyl]-1-(1-methylpiperidin-4-yl)urea
• CAS: 1134815-69-2
• 化学式: C₂₅H₃₄FN₃O₃
• 分子量: 443.6
• InChiKey: PIMCCOKGYRQRGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  65
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS
  申请人：Uldam Henriette Kold

  公开号：US20090082342A1

  公开（公告）日：2009-03-26

  Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.

  本文披露了公式(I)、(II)、(III)、(IV)和(V)化合物的分离形式，或其药物可接受的盐、前药、水合物、溶剂化物、多晶形或酯。本文还披露了抑制5-羟色胺受体活性的方法、抑制5-羟色胺受体激活的方法，以及缓解或治疗各种疾病状况和副作用的方法。
• CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS
  申请人：Hacksell Uli

  公开号：US20090082388A1

  公开（公告）日：2009-03-26

  As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities.

  如本文所述，联合使用pimavanserin和改善一个或多个胆碱能异常的药物可以增强该药物的疗效。本文还披露了包括pimavanserin和改善一个或多个胆碱能异常的药物在内的组合物。本文还披露了一种改善或治疗由一个或多个胆碱能异常特征的疾病状况的方法，该方法可以包括使用pimavanserin和改善一个或多个胆碱能异常的药物。
• [EN] CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS<br/>[FR] CO-ADMINISTRATION DE PIMAVANSÉRINE AVEC D'AUTRES AGENTS
  申请人：ACADIA PHARM INC

  公开号：WO2009039460A2

  公开（公告）日：2009-03-26

  As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities.
• [EN] N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE N-SUBSTITUÉS EN TANT QU'AGENTS RÉCEPTEURS DE LA SÉROTONINE
  申请人：ACADIA PHARM INC

  公开号：WO2009039461A2

  公开（公告）日：2009-03-26

  Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.